Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, these data support the hypothesis that the API2-MALT1 fusion protein can contribute to MALT lymphoma formation via increased NF-kappaB activation.
|
16707452 |
2006 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
API2-MALT1 translocation was detected in 1 (7%) of 14 DLBCL cases and in 1 (17%) of 6 MALT lymphoma cases.
|
16484127 |
2006 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
One hundred thirty-three paraffin-embedded North American primary MALT lymphoma specimens from diverse anatomic sites were studied by fluorescence in situ hybridization (FISH) using probes for API2-MALT1, IGH-MALT1, IGH-BCL10, IGH-FOXP1, IGH, +/- centromeres 3, 7, 12, and 18, and a subset (n=74) were analyzed using FISH probes for IGK, IGL, and BCL6.
|
17122510 |
2006 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
t(11;18)(q21;q21) occurs specifically in mucosa-associated lymphoid tissue (MALT) lymphoma and the translocation generates a functional API2-MALT1 fusion product that activates nuclear factor (NF)kappaB. t(11;18) positive lymphomas usually lack the chromosomal aberrations and microsatellite alterations frequently seen in the translocation-negative MALT lymphomas.
|
16512826 |
2006 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Helicobacter pylori-negative / API2-MALT1 translocation-negative low-grade MALT lymphoma.
|
16952043 |
2006 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Delving deeper into MALT lymphoma biology.
|
16395399 |
2006 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The most frequently recurring translocations in mucosa-associated lymphoid tissue (MALT) B-cell non-Hodgkin lymphoma, t(11;18)(q21;q21) and t(14;18)(q32; q21), lead to formation of an API2-MALT1 fusion or IgH-mediated MALT1 overexpression.
|
15598810 |
2005 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This stability of API2-MALT1 may thus result in inappropriate nuclear factor (NF)-kappaB activation, thereby contributing to the pathogenesis of MALT lymphoma.
|
15711920 |
2005 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MALT1, BCL10 (B-cell lymphoma 10), and API2 (apoptosis inhibitor 2)-MALT1 are key molecules in mucosa-associated lymphoid tissue (MALT) lymphomagenesis.
|
16123224 |
2005 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
The frequency of API2-MALT1 transcript was lower in thyroid MALT lymphoma(1/12) but similar in pulmonary and gastrointestinal MALT lymphoma.
|
15696476 |
2005 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The most frequent chromosome translocation associated with MALT lymphoma is t(11;18)(q21;q21), which generates a chimeric protein of c-IAP2 and MALT1/paracaspase.
|
15894263 |
2005 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The detection of API2-MALT1 fusion as carried out with these specimens would be useful as an ancillary assay for the diagnosis, staging, and follow-up of pulmonary MALT lymphoma.
|
16105761 |
2005 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mucosa-associated lymphoid tissue (MALT) lymphoma is specifically associated with t(11;18)(q21;q21), t(1;14)(p22;q32) and t(14;18)(q32;q21). t(11;18)(q21;q21) fuses the N-terminus of the API2 gene to the C-terminus of the MALT1 gene and generates a functional API2-MALT1 product. t(1;14)(p22;q32) and t(14;18)(q32;q21) bring the BCL10 and MALT1 genes respectively to the IGH locus and deregulate their expression.
|
15682443 |
2005 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The API2-MALT1 fusion was detected by multiplex reverse transcription polymerase chain reaction in 25/60 (42%) cases of MALT lymphoma, but none of 11 DLBLs.
|
15832193 |
2005 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
T(11;18) results in a chimeric fusion between the API2 and MALT1 genes and is specifically associated with gastric MALT lymphomas that do not respond to eradication of H. pylori.
|
15694184 |
2005 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Taken together, our results strongly indicated that API2-MALT1 possesses a novel mechanism of self-activation by up-regulating its own expression in t(11;18)(q21;q21)-carrying MALT lymphomas, highlighting a positive feedback-loop pathway resulting in unremitting NF-kappaB activation.
|
15982633 |
2005 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In primary pulmonary MALT lymphomas, cytogenetic abnormalities are common (75%) and heterogeneous, encompassing API2-MALT1 and IGH-MALT1, which are mutually exclusive, as well as aneuploidy, which may be present in the latter but is rare in the former.
|
14574335 |
2004 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion.
|
15577674 |
2004 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
t(11;18)(q21;q21) resulting in the API2-MALT1 fusion transcript is an exclusive finding in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
|
15452377 |
2004 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Antiapoptotic function of apoptosis inhibitor 2-MALT1 fusion protein involved in t(11;18)(q21;q21) mucosa-associated lymphoid tissue lymphoma.
|
15150097 |
2004 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Three distinct chromosomal translocations, t(11;18), t(1;14), and t(14;18), involving the API2-MALT1 fusion protein, BCL10, and MALT1 have been convincingly implicated in the pathogenesis of mucosa-associated lymphoid tissue (MALT) lymphomas.
|
15540895 |
2004 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MALT lymphomas are characterized genetically by the t(11;18)(q21;q21) translocation, which yields chimeric transcripts encoding structurally distinct API2/MALT1 fusion proteins.
|
15184680 |
2004 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Intestinal MALT lymphomas with API2-MALT1 expression have distinctive forms of infiltration compared with those without translocation.
|
15363040 |
2004 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
Biomarker
|
disease |
LHGDN |
Intestinal MALT lymphomas with API2-MALT1 expression have distinctive forms of infiltration compared with those without translocation.
|
15363040 |
2004 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A possible API2-MLT fusion transcript specific to t(11;18)(q21;q21) was examined by means of reverse transcription-polymerase chain reaction (RT-PCR) in tumours from 47 cases of primary gastrointestinal lymphoma (28 low grade mucosa associated lymphoid tissue (MALT) lymphomas, four low grade MALT lymphomas with a high grade component, nine secondary diffuse large B cell lymphomas, four primary diffuse large B cell lymphomas, and two T cell lymphomas).
|
12499431 |
2003 |